Abstract
We wish to clarify key points raised in a recent commentary (Asgari, 2016) about our report on survival outcomes after multiple primary invasive melanomas (Youlden et al., 2016) published in the November 2016 issue of The Journal of Investigative Dermatology.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
